Pediatric Mucormycosis Treatment & Management
- Author: Meera Varman, MD; Chief Editor: Russell W Steele, MD more...
Approach Considerations
Mucormycosis is often life threatening. A combination of a high index of suspicion with prompt diagnosis and medical and surgical care are vital in the management of mucormycosis. Patients' survival rates also depend on resolution of their underlying condition. If mucormycosis progresses and if the underlying condition remains uncontrolled, death usually ensues.
Care of a pediatric patient with mucormycosis should involve several pediatric subspecialists, depending on the patient's underlying risk factors and the extent of disease. Therefore, if the child has an underlying malignancy, the following physicians should be involved in the child's care: oncologist, infectious disease specialist, surgeon (ear, nose, and throat [ENT] specialist and neurosurgeon, if the patient has rhinocerebral disease), and critical care specialists.
Clinical Management
Underlying comorbidities such as hyperglycemia, acidosis in diabetic patients, nutritional problems, neutropenia, lymphopenia, and immunosuppression must be addressed.
The drug of choice for treating mucormycosis is amphotericin B, with a dosage of 1-1.5 mg/kg/d. Liposomal amphotericin B at dosages higher than these have also been used to treat disseminated disease.[8, 9] Some authors have suggested doses as high as 10-15 mg/kg. A term neonate who was diagnosed with facial mucormycosis after liver and small bowel transplantation survived after wide excision and 26 weeks of treatment with liposomal amphotericin B.[10]
Azoles (eg, fluconazole, itraconazole) are not helpful in the treatment of mucormycosis. Among relatively new triazoles, posaconazole is effective against mucormycosis. This agent has an oral formulation and undergoes liver metabolism. Posaconazole may be effective compared with other azoles against molds, including mucormycosis.[11, 12] Studies are being conducted to evaluate combination antifungal therapies.
Hyperbaric oxygen has been noted to reduce the morbidity and mortality when given in combination with medical and surgical therapy, with a 50% survival rate.[13]
Surgical Intervention
Surgical debridement should be undertaken early in the course of the illness, especially in cases of rhinocerebral mucormycosis. Instilling amphotericin B into abscess cavities after debridement has been suggested. Repeat surgery may be necessary to effectively eliminate all necrotic tissue in patients who survive. Reconstructive surgery is inevitable for those who have disfigurement due to severe rhinocerebral mucormycosis.
Long-Term Monitoring
Close observation of patients who were treated and who survived the acute mucormycosis infection is important, because chronic manifestation of mucormycosis or late sequelae is possible.
In patients with rhinocerebral mucormycosis, cerebral abscess formation, cavernous sinus thrombosis, and thromboembolism of the internal carotid artery should be suspected as complications.
Studies in adults have demonstrated some benefit with the use of high-efficiency particulate air (HEPA) filters and different chelating agents instead of deferoxamine to decrease the risk of mucormycosis.
No method to prevent mucormycosis is recognized.
Richardson M, Koukila-Kahkola P, Shankland G. Rhizopus, Rhizomucor, Absidia, and other agents of systemic and subcutaneous zygomycoses. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA , Yolken RH, eds. Manual of Clinical Microbiology. 9th ed. Washington, DC: American Society of Microbiology; 2007.
Sugar A. Agents of mucormycosis and related species. In: Mandell GL, Bennet JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Churchill Livingstone; 2009:Chapter 259.
Wiedermann BL. Zygomycosis. In: Feigen RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, eds. Textbook of Pediatric Infectious Diseases. 6th ed. Philadelphia, Pa: Saunders; 2009.
Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med. Mar 2001;125(3):375-8. [Medline].
Simbli M, Hakim F, Koudieh M, Tleyjeh IM. Nosocomial post-traumatic cutaneous mucormycosis: a systematic review. Scand J Infect Dis. 2008;40(6-7):577-82. [Medline].
Robertson AF, Joshi VV, Ellison DA, Cedars JC. Zygomycosis in neonates. Pediatr Infect Dis J. Aug 1997;16(8):812-5. [Medline].
Kline MW. Mucormycosis in children: review of the literature and report of cases. Pediatr Infect Dis. Nov-Dec 1985;4(6):672-6. [Medline].
Garbino J, Myers C, Ambrosioni J, Gumy-Pause F. Report of a successful treatment of pulmonary Cunninghamella bertholletiae infection with liposomal amphotericin and posaconazole in a child with GvHD and review of the literature. J Pediatr Hematol Oncol. Mar 2010;32(2):85-7. [Medline].
Rüping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flörl C, Beisel C, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. Feb 2010;65(2):296-302. [Medline].
Dave SP, Vivero RJ, Roy S. Facial cutaneous mucormycosis in a full-term infant. Arch Otolaryngol Head Neck Surg. Feb 2008;134(2):206-9. [Medline].
Scheinfeld N. A review of the new antifungals: posaconazole, micafungin, and anidulafungin. J Drugs Dermatol. Dec 2007;6(12):1249-51. [Medline].
Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. Jan 25 2007;356(4):335-47. [Medline].
Kaide CG, Khandelwal S. Hyperbaric oxygen: applications in infectious disease. Emerg Med Clin North Am. May 2008;26(2):571-95, xi. [Medline]. [Full Text].
Garg PK, Gupta N, Gautam V, Hadke NS. Gastric zygomycosis: unusual cause of gastric perforation in an immunocompetent patient. South Med J. Apr 2008;101(4):449-50. [Medline].
Goel S, Carter JE, Culpepper M, Kahn AG. Primary renal zygomycotic infarction mimicking renal neoplasia in an immunocompetent patient. Am J Med Sci. Oct 2009;338(4):330-3. [Medline].
Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. Apr 15 2005;191(8):1350-60. [Medline].
Singh N, Aguado JM, Bonatti H, Forrest G, Gupta KL, Safdar N, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis. Sep 15 2009;200(6):1002-11. [Medline].
Print
